Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02085967 · ClinicalTrials.gov registry record · Phase 1
A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT02085967: Completed Phase 1 study, sponsored by Eisai.
NCT02085967 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 106 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02085967, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
This study will be a single center, open-label, drug-drug interaction study in healthy male and female subjects. The study will consist of 2 parts. In Part A, the effects of steady-state dosing of a strong CYP3A inhibitor (itraconazole) or inducer (rifampin) on the pharmacokinetics of E2006 and metabolites will be assessed. Approximately 30 subjects will be sequentially assigned to 1 of 2 treatment groups to receive itraconazole or rifampin in equal numbers (approximately 15 subjects per group). The itraconazole treatment group will be fully enrolled before enrollment is initiated for the rifampin treatment group. In Part B, the effects of steady-state dosing of E2006 on the pharmacokinetics of midazolam, a substrate of CYP3A, plus bupropion, a substrate of CYP2B6, will be assessed in approximately 24 subjects. The 2 study parts can be conducted in parallel.
Primary Outcome
Area under the concentration-time curve from zero time to time of last quantifiable concentration
Interventions
- DRUG E2006
- DRUG rifampin 600 mg
- DRUG itraconazole 200 mg
- DRUG midazolam 2 mg with bupropion 75 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
What the finished NCT02085967 record still lists
NCT02085967 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% higher).
The record links to 0 conditions, and to 4 interventions - of which E2006 is the first listed.
NCT02085967 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02085967 about?
NCT02085967 is a clinical study titled "A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion". This study will be a single center, open-label, drug-drug interaction study in healthy male and female subjects. The study will consist of 2 parts. In Part A, the effects of steady-state dosing of a strong CYP3A inhibitor (itraconazole) or inducer (rifampin) on the pharmacokinetics of E2006 and meta...
What is the current status of trial NCT02085967?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2014-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02085967?
The interventions under investigation include: E2006 (DRUG), rifampin 600 mg (DRUG), itraconazole 200 mg (DRUG), midazolam 2 mg with bupropion 75 mg (DRUG).
Who is sponsoring clinical trial NCT02085967?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02085967's enrollment target sits among peer trials
106 531st of 2000 higher than 1,468 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia